Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
In the post-Brexit era, Britain must rapidly harmonize national and European law, secure unfettered access to global talent and address funding shortfalls to ensure continued leadership in the life sciences.
A detailed look at the economic impact of university-licensed life science startups across the United States reveals vast differences in the effectiveness of different regions to create ventures and sustain them as viable entities.
The biopharmaceutical industry’s positive regulatory momentum carried on through 2019, despite an early-year government shutdown, a data manipulation scandal around a high-profile approval, and many months without permanent leadership at the FDA.